Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Korro Bio, Inc. (KRRO : NSDQ)

• Company Description    Korro Bio Inc. is an RNA editing company focused on the discovery and development of a new class of precision genetic medicines for both rare and highly prevalent diseases. Korro Bio Inc., formerly known as Frequency Therapeutics Inc., is based in LEXINGTON, Mass. Number of Employees: 58

• Price / Volume Information    Yesterday's Closing Price: $11.61 Daily Weekly Monthly 20 Day Moving Average: 112,808 shares Shares Outstanding: 14.42 (millions) Market Capitalization: $167.45 (millions) Beta: 3.07 52 Week High: $55.89 52 Week Low: $5.20 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -14.60% -18.77% 12 Week -4.05% -11.30% Year To Date 44.94% 28.55%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 60 FIRST STREET 2ND FLOOR SUITE 250 - CAMBRIDGE,MA 02141 USA ph: 617-468-1999 fax: - ir@korrobio.com http://www.korrobio.com

• General Corporate Information    Officers Ram Aiyar - President; Chief Executive Officer and Director Oliver Dolan - Senior Vice President; Finance Ali Behbahani - Director Nessan Bermingham - Director Jean-Francois Formela - Director Peer Information Korro Bio, Inc. (GSAC) Korro Bio, Inc. (CASIF) Korro Bio, Inc. (ALCD.) Korro Bio, Inc. (OMNN) Korro Bio, Inc. (CGPI.) Korro Bio, Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 500946108 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/11/26 Share - Related Items Shares Outstanding: 14.42 Most Recent Split Date: 11.00 (0.02:1) Beta: 3.07 Market Capitalization: $167.45 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.43 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-5.38 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.40 Price/Cash Flow: - Price / Sales: 26.20 EPS Growth vs. Year Ago Period: 32.13% vs. Previous Quarter: 68.23% Sales Growth vs. Year Ago Period: -43.11% vs. Previous Quarter: 18.53% ROE 03/31/26 - -117.86 12/31/25 - -115.95 09/30/25 - -68.87 ROA 03/31/26 - -71.04 12/31/25 - -71.32 09/30/25 - -45.91 Current Ratio 03/31/26 - 8.13 12/31/25 - 6.90 09/30/25 - 6.71 Quick Ratio 03/31/26 - 8.13 12/31/25 - 6.90 09/30/25 - 6.71 Operating Margin 03/31/26 - - 12/31/25 - -1,834.48 09/30/25 - -1,199.53 Net Margin 03/31/26 - - 12/31/25 - -1,834.48 09/30/25 - -1,199.53 Pre-Tax Margin 03/31/26 - -2,935.09 12/31/25 - -1,824.52 09/30/25 - -1,198.11 Book Value 03/31/26 - 8.29 12/31/25 - 5.46 09/30/25 - 10.54 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00

Powered by Zacks Investment Research ©